Skip to content

Bausch + Lomb Acquires Elios Vision

๐๐š๐ฎ๐ฌ๐œ๐ก + ๐‹๐จ๐ฆ๐› ๐š๐œ๐ช๐ฎ๐ข๐ซ๐ž๐ฌ ๐„๐ฅ๐ข๐จ๐ฌ ๐•๐ข๐ฌ๐ข๐จ๐ง

๐Ÿ‘ Bausch + Lomb has acquired Elios Vision, enhancing its glaucoma treatment portfolio with the innovative Excimer Laser Trabeculostomy (ELIOS) system. This minimally invasive glaucoma surgery (MIGS) technology lowers intraocular pressure by creating microchannels in the eyeโ€™s drainage system, offering a safer alternative to traditional surgeries.

๐Ÿ‘€ With its proven success in Europe and ongoing U.S. clinical trials, ELIOS Vision's technology positions Bausch + Lomb as a leading player in the growing glaucoma treatment market.